close
  • home Home

  • linked_services Solutions keyboard_arrow_down

  • experiment Services keyboard_arrow_down

  • support Support & Resources keyboard_arrow_down

  • apartment Company keyboard_arrow_down

  • mail Contact

  • Solutions
    keyboard_arrow_down
  • Services
    keyboard_arrow_down
  • Support & Resources
    keyboard_arrow_down
  • Company
    keyboard_arrow_down
  • Contact
Randox Health search menu

The RIQAS CYFRA 21-1 EQA programme is designed to cover the analysis of CYFRA 21-1 in clinical laboratories when monitoring the response to treatment of cancers such as non-small cell lung carcinoma, cervical, breast and bladder cancer.

Lyophilised material for enhanced stability

Submit results and view reports online via RIQAS.Net

World's largest EQA scheme ensures peer groups are maximised

Monthly reporting for earlier identification of test system errors

Cycle Starts - March 2026

Accredited to ISO17043:2023 standard via RIQAS flexible scope

Get in touch to discover more

To find out more about RIQAS EQA or to get in touch with your local Randox Representative, enquire now.

DescriptionFrequencySizeCat No
CYFRA 21-1Monthly12 x 1 mlRQ9175

Parameters

  • CYFRA 21-1 (Cytokeratin 19 fragment)

Please note, product availability may vary country to country.

Related RIQAS EQA Programmes

Immunoassay

Immunoassay Speciality 1

Immunoassay Speciality 2

Acusera QC
Complete QC Solutions for Results you Can Trust
RIQAS Brochure
Randox International Quality Assessment Scheme
QCMD
QCMD EQA/PT Schemes for Molecular Infectious Disease Testing.